Calculate Your Salary Ranking
Home > Micromet Salary

Micromet Salary
  • 29
  • 67
  • 96

Micromet average salary is $229,882, median salary is $229,882 with a salary range from $229,882 to $229,882.
Micromet salaries are collected from government agencies and companies. Each salary is associated with a real job position. Micromet salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
229,882
Average
229,882
Median
229,882
High
229,882
Total 1 Micromet Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Chief Executive Officer 229,882-229,882 Bethesda, MD, 20813 2011 Micromet Chief Executive Officer Salaries (1)
Micromet Bethesda, MD Salaries
1
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Micromet Salaries (August 25, 2016)
Assistant Professor University of Oklahoma $42,860 Norman, OK, 73019 01/05/2015
General OMRON $65,998 Houston, TX, 77001 09/07/2015

Micromet salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Micromet Information
  • Micromet , Inc.
  • Industry: BioTech/Drugs
  • City: Bethesda, MD
  • Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company¡¯s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin¡¯s lymphoma (NHL). A